scholarly journals 600.02 1-Year Outcomes of Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Patients at Intermediate Surgical Risk: A Propensity-Match Analysis from the SURTAVI Trial

2019 ◽  
Vol 12 (4) ◽  
pp. S42-S43 ◽  
Author(s):  
Steven J. Yakubov ◽  
Jeffrey J. Popma ◽  
Nicolas M. Van Mieghem ◽  
Patrick W. Serruys ◽  
Arie-Pieter Kappetein ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Transcatheter Aortic Valve Replacement ◽  
Surgical Aortic Valve Replacement ◽  
Match Analysis ◽  
Surgical Risk ◽  
Propensity Match ◽  
Transcatheter Aortic Valve

scholarly journals Patient-Tailored Aortic Valve Replacement

2021 ◽  
Vol 8 ◽  
Author(s):  
Ole De Backer ◽  
Ivan Wong ◽  
Ben Wilkins ◽  
Christian Lildal Carranza ◽  
Lars Søndergaard
Keyword(s):  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Transcatheter Aortic Valve Replacement ◽  
Aortic Valve Disease ◽  
Valve Disease ◽  
Surgical Aortic Valve Replacement ◽  
Patient Centered ◽  
Surgical Risk ◽  
Transcatheter Aortic Valve

Contemporary surgical and transcatheter aortic valve interventions offer effective therapy for a broad range of patients with severe symptomatic aortic valve disease. Both approaches have seen significant advances in recent years. Guidelines have previously emphasized ‘surgical risk’ in the decision between surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR), although this delineation becomes increasingly obsolete with more evidence on the effectiveness of TAVR in low surgical risk candidates. More importantly, decisions in tailoring aortic valve interventions should be patient-centered, accounting not only for operative risk, but also anatomy, lifetime management and specific co-morbidities. Aspects to be considered in a patient-tailored aortic valve intervention are discussed in this article.

Clinical trials of transcatheter aortic valve replacement

Heart ◽  
2019 ◽  
Vol 105 (Suppl 2) ◽  
pp. s6-s9 ◽  
Author(s):  
Karim Al-Azizi ◽  
Mohanad Hamandi ◽  
Michael Mack
Keyword(s):  
Clinical Trials ◽  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Transcatheter Aortic Valve Replacement ◽  
Severe Aortic Stenosis ◽  
Surgical Aortic Valve Replacement ◽  
Surgical Risk ◽  
Transcatheter Aortic Valve ◽  
Risk Patients

Transcatheter aortic valve replacement(TAVR) has emerged as an effective treatment option in patients with severe aortic stenosis, in large part due to a robust evidence base generated by a series of randomised controlled trials (RCTs). During the past decade more than 15 000 patients have been randomised worldwide in nine clinical trials, mostly for regulatory approval in the USA, making it one of the most carefully scrutinised medical devices at the time of introduction into clinical practice. Initial trials were performed in inoperable or extreme risk patients compared to medical therapy and demonstrated superiority. Subsequent RCTs compared TAVR to surgical aortic valve replacement in high and intermediate surgical risk patients and TAVR was found to be non-inferior in all studies. RCTs of low surgical risk patients have completed enrolment and 1 year outcomes will be available in early 2019. The details of the trials, trial results, outcomes and remaining clinical questions are summarised in this article.

scholarly journals Valve-in-Valve Transcatheter Aortic Valve Replacement Versus Redo Surgical Aortic Valve Replacement

2021 ◽  
Vol 14 (2) ◽  
pp. 211-220 ◽  
Author(s):  
Michel Pompeu B.O. Sá ◽  
Jef Van den Eynde ◽  
Matheus Simonato ◽  
Luiz Rafael P. Cavalcanti ◽  
Ilias P. Doulamis ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Transcatheter Aortic Valve Replacement ◽  
Surgical Aortic Valve Replacement ◽  
Transcatheter Aortic Valve ◽  
Valve In Valve
Sign in / Sign up

Export Citation Format

Share Document